Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009954 | 0.85 | PLA2G10 (0.48) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL15750780 | 0.84 | CCNC (0.42) | GRM2RIPK2 | |
| SCHEMBL17259224 | 0.81 | CHRNA7 (0.58) | KDM4EALDH1A1HPGDCHRNA7 | |
| SCHEMBL15750638 | 0.77 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL15750440 | 0.77 | MKNK1 (0.45) | ALDH1A1RIPK2 | |
| SCHEMBL9209581 | 0.74 | MEN1 (0.60) | CHRNA7MEN1KMT2AATMPTGS2 | |
| SCHEMBL17259299 | 0.74 | KDM4E (0.37) | KDM4EALDH1A1CHRNA7KMT2AATM | |
| SCHEMBL17259225 | 0.74 | KDM4E (0.40) | KDM4EALDH1A1CHRNA7PTGS2KCNH2 | |
| SCHEMBL27694888 | 0.73 | KMT2A (0.71) | CHRNA7MEN1KMT2AATMPTGS2 | |
| SCHEMBL28035847 | 0.73 | SMPD1 (0.67) | KDM4EALDH1A1HPGDSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | KDM4E 4055/4885ALDH1A1 1426/4885HPGD 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.